Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

194 Press Releases
DateTitleCompany
16 Sep 11 New data for once-daily linagliptin show durable efficacy over two years Boehringer Ingelheim,
Published by
Business Wire
30 Aug 11 Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib* Boehringer Ingelheim,
Published by
PharmiWeb.com
29 Aug 11 Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib* Boehringer Ingelheim,
Published by
Business Wire
29 Aug 11 €1 Million Awarded to Winning Projects Which Aim to Prevent Atrial Fibrillation-Related Stroke Boehringer Ingelheim GmbH,
Published by
Business Wire
28 Aug 11 Pradaxa® (dabigatran etexilate) 150mg bid provides consistent stroke reduction over warfarin in patients with atrial fibrillation taking antiplatelet or other concomitant therapies Boehringer Ingelheim,
Published by
Business Wire
26 Aug 11 Pradaxa® (Dabigatran Etexilate) Revolutionizes Stroke Prevention in Atrial Fibrillation Boehringer Ingelheim,
Published by
Business Wire
26 Aug 11 Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe Boehringer Ingelheim and Eli Lilly,
Published by
PharmiWeb.com
25 Aug 11 Trajenta® (linagliptin) Receives Approval for the Treatment of Type 2 Diabetes in Europe Boehringer Ingelheim,
Published by
Business Wire
15 Aug 11 ?Pradaxa® (dabigatran etexilate), the first new oral anticoagulant for stroke prevention in atrial fibrillation in over 50 years, now licensed for use in the UKi Boehringer Ingelheim,
Published by
Reynolds-MacKenzie
04 Aug 11 Breakthrough Therapy PRADAXA® (Dabigatran Etexilate) First Drug in 50 Years to Gain Approval for Stroke Prevention in Atrial Fibrillation in Europe Boehringer Ingelheim,
Published by
Business Wire
27 Jun 11 New data for linagliptin* show clinically meaningful efficacy similar to glimepiride but with fewer cardiovascular events Boehringer Ingelheim,
Published by
Business Wire
24 Jun 11 Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe Boehringer Ingelheim,
Published by
Business Wire
22 Jun 11 Global Stroke Prevention Awareness Initiative Draws Two Million Votes around the World Boehringer Ingelheim GmbH,
Published by
Business Wire
17 Jun 11 New Data Confirm Superior Blood Pressure Reductions in Diabetic Patients Treated with TWYNSTA® Compared to Amlodipine Alone Boehringer Ingelheim,
Published by
Business Wire
26 May 11 Actress Jane Seymour’s appeal generates over one million votes to help prevent atrial fibrillation-related strokes Boehringer Ingelheim GmbH,
Published by
Business Wire
03 May 11 FDA approves linagliptin tablets for the treatment of type 2 diabetes Boehringer Ingelheim,
Published by
Business Wire
18 Apr 11 Dabigatran etexilate (Pradaxa®) recommended for approval in atrial fibrillation for stroke prevention in Europe Boehringer Ingelheim
04 Apr 11 Boehringer Ingelheim’s lead hepatitis C compound moves into Phase III – the first within the BI HCV portfolio Boehringer Ingelheim,
Published by
Business Wire
24 Mar 11 Dabigatran etexilate is cost-effective for stroke prevention in atrial fibrillation, particularly in real-world clinical practice Boehringer Ingelheim,
Published by
Business Wire
22 Mar 11 Actress Jane Seymour takes up the fight against common heart rhythm disorder, atrial fibrillation and its link to stroke Boehringer Ingelheim,
Published by
Business Wire
14 Mar 11 New Hepatitis C Data from Boehringer Ingelheim HCV Portfolio to Be Presented at EASL Boehringer Ingelheim,
Published by
Business Wire
11 Jan 11 Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide Boehringer Ingelheim,
Published by
Business Wire
08 Nov 10 Dabigatran Etexilate Demonstrates Substantial Clinical Benefits in Atrial Fibrillation Patients with Prior Stroke or Transient Ischaemic Attack Boehringer Ingelheim,
Published by
Business Wire
20 Oct 10 US FDA Approves Pradaxa® (dabigatran etexilate) – a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation Boehringer Ingelheim,
Published by
Business Wire
11 Oct 10 Afatinib (BIBW 2992*) triples progression free survival Boehringer Ingelheim,
Published by
PharmiWeb.com
22 Sep 10 New phase III data further support the safety and efficacy profile of Boehringer Ingelheim’s investigational drug linagliptin Boehringer Ingelheim
22 Sep 10 Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer Boehringer Ingelheim,
Published by
PharmiWeb.com
10 Sep 10 A new era for patients with atrial fibrillation - dabigatran etexilate leading the way in new oral anticoagulants Boehringer Ingelheim,
Published by
Reynolds-MacKenzie
29 Aug 10 Sub-Analysis Shows Primary Benefits seen with RE-LY® are Independent of Level of Centre-Based International Normalized Ratio Control Boehringer Ingelheim GmbH,
Published by
Business Wire
29 Aug 10 New Global Campaign Aims to Prevent as Many as 1 Million Atrial Fibrillation-Related Strokes Boehringer Ingelheim GmbH,
Published by
Business Wire
Advertising